HK1009331A1 - Enantiomeric 1-phenyl-2-(2-pyridinyl) ethylamine for the treatment of neurodegenerative disorders - Google Patents

Enantiomeric 1-phenyl-2-(2-pyridinyl) ethylamine for the treatment of neurodegenerative disorders Download PDF

Info

Publication number
HK1009331A1
HK1009331A1 HK98110056A HK98110056A HK1009331A1 HK 1009331 A1 HK1009331 A1 HK 1009331A1 HK 98110056 A HK98110056 A HK 98110056A HK 98110056 A HK98110056 A HK 98110056A HK 1009331 A1 HK1009331 A1 HK 1009331A1
Authority
HK
Hong Kong
Prior art keywords
phenyl
pyridineethanamine
pharmaceutically acceptable
treatment
compound
Prior art date
Application number
HK98110056A
Other languages
German (de)
English (en)
French (fr)
Chinese (zh)
Other versions
HK1009331B (en
Inventor
Conrad Griffith Ronald
John Murray Robert
Balestra Michael
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929207339A external-priority patent/GB9207339D0/en
Priority claimed from GB929208290A external-priority patent/GB9208290D0/en
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Publication of HK1009331B publication Critical patent/HK1009331B/en
Publication of HK1009331A1 publication Critical patent/HK1009331A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
HK98110056A 1992-04-03 1993-04-01 Enantiomeric 1-phenyl-2-(2-pyridinyl) ethylamine for the treatment of neurodegenerative disorders HK1009331A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9207339 1992-04-03
GB929207339A GB9207339D0 (en) 1992-04-03 1992-04-03 Pharmaceutical compound
GB929208290A GB9208290D0 (en) 1992-04-15 1992-04-15 Pharmaceutical compound having neuroprotective properties
GB9208290 1992-04-15
PCT/GB1993/000689 WO1993020052A1 (en) 1992-04-03 1993-04-01 Enantiomeric 1-phenyl-2-(2-pyridinyl)ethylamine for the treatment of neurodegenerative disorders

Publications (2)

Publication Number Publication Date
HK1009331B HK1009331B (en) 1999-05-28
HK1009331A1 true HK1009331A1 (en) 1999-05-28

Family

ID=26300643

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98110056A HK1009331A1 (en) 1992-04-03 1993-04-01 Enantiomeric 1-phenyl-2-(2-pyridinyl) ethylamine for the treatment of neurodegenerative disorders

Country Status (29)

Country Link
EP (1) EP0633879B1 (enExample)
JP (2) JP3120810B2 (enExample)
KR (1) KR100259567B1 (enExample)
CN (1) CN1044367C (enExample)
AT (1) ATE163925T1 (enExample)
AU (2) AU3897693A (enExample)
CA (1) CA2133427C (enExample)
CZ (1) CZ288519B6 (enExample)
DE (1) DE69317411T2 (enExample)
DK (1) DK0633879T3 (enExample)
DZ (1) DZ1677A1 (enExample)
ES (1) ES2115055T3 (enExample)
FI (1) FI105025B (enExample)
HK (1) HK1009331A1 (enExample)
HU (1) HU211529A9 (enExample)
IL (1) IL105276A (enExample)
MA (1) MA22866A1 (enExample)
MX (1) MX9301935A (enExample)
MY (1) MY110149A (enExample)
NO (1) NO302170B1 (enExample)
NZ (1) NZ251384A (enExample)
PL (1) PL180014B1 (enExample)
RU (1) RU2128650C1 (enExample)
SG (1) SG47948A1 (enExample)
SK (1) SK281258B6 (enExample)
TW (1) TW282455B (enExample)
UA (1) UA29437C2 (enExample)
WO (1) WO1993020052A1 (enExample)
ZA (1) ZA932415B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9320273D0 (en) * 1993-04-01 1993-11-17 Fisons Corp Compound useful in therapy
ES2083972T3 (es) * 1988-08-12 1996-05-01 Astra Ab Arilalquil-aminas y -amidas con propiedades anticonvulsivas y neuroprotectoras.
ZA942140B (en) * 1993-04-01 1994-10-03 Fisons Corp Salt of (S)-alpha-phenyl-2-pyridineethanamine useful in therapy
SE9901077D0 (sv) * 1999-03-23 1999-03-23 Astra Ab Novel use
SE9901237D0 (sv) * 1999-04-06 1999-04-06 Astra Ab Novel use
SE9901340D0 (sv) 1999-04-15 1999-04-15 Astra Pharma Prod Novel process
HUP0202143A3 (en) * 1999-07-28 2003-12-29 Ortho Mcneil Pharm Inc Amine and amide derivatives as ligands for the neuropeptide y y5 receptor pharmaceutical compositions containing them and their use
WO2007017652A2 (en) * 2005-08-10 2007-02-15 Astrazeneca Ab Arylakylamines for the treatment of cancer
KR20110097996A (ko) * 2008-12-24 2011-08-31 아스트라제네카 아베 에탄아민 화합물 및 우울증의 치료를 위한 그의 용도
WO2013088135A1 (en) * 2011-12-14 2013-06-20 Astrazeneca Ab Gabr-a2 diagnostic
KR102336426B1 (ko) * 2013-11-05 2021-12-08 아스트라제네카 아베 Nmda 길항제 전구약물
BR112022025900A2 (pt) * 2020-06-23 2023-01-10 Biohaven Therapeutics Ltd Formulações tópicas de (1s)-1-fenil-2-piridin-2-iletanamina

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2673588A (en) * 1987-12-11 1989-06-15 Laboratoires Syntex 1,4-dihydropyridine derivatives as neuroprotective compounds
ES2083972T3 (es) * 1988-08-12 1996-05-01 Astra Ab Arilalquil-aminas y -amidas con propiedades anticonvulsivas y neuroprotectoras.

Also Published As

Publication number Publication date
CZ288519B6 (cs) 2001-07-11
EP0633879A1 (en) 1995-01-18
NO943645D0 (no) 1994-09-30
RU2128650C1 (ru) 1999-04-10
ATE163925T1 (de) 1998-03-15
KR100259567B1 (ko) 2000-07-01
ZA932415B (en) 1993-10-22
DZ1677A1 (fr) 2002-02-17
CA2133427C (en) 2003-06-10
WO1993020052A1 (en) 1993-10-14
JP3120810B2 (ja) 2000-12-25
MX9301935A (es) 1994-08-31
FI105025B (fi) 2000-05-31
RU94042465A (ru) 1996-07-20
DE69317411D1 (de) 1998-04-16
UA29437C2 (uk) 2000-11-15
SK117794A3 (en) 1995-05-10
NZ251384A (en) 1996-10-28
NO302170B1 (no) 1998-02-02
CN1081669A (zh) 1994-02-09
MA22866A1 (fr) 1993-12-31
SG47948A1 (en) 1998-04-17
JPH07505385A (ja) 1995-06-15
HU211529A9 (en) 1995-11-28
JP2000319259A (ja) 2000-11-21
EP0633879B1 (en) 1998-03-11
TW282455B (enExample) 1996-08-01
IL105276A0 (en) 1993-08-18
AU7545696A (en) 1997-02-13
AU705419B2 (en) 1999-05-20
CN1044367C (zh) 1999-07-28
SK281258B6 (sk) 2001-01-18
FI944546L (fi) 1994-09-30
DK0633879T3 (da) 1998-09-28
CA2133427A1 (en) 1993-10-14
FI944546A0 (fi) 1994-09-30
PL180014B1 (pl) 2000-11-30
AU3897693A (en) 1993-11-08
NO943645L (no) 1994-11-16
ES2115055T3 (es) 1998-06-16
IL105276A (en) 1997-06-10
CZ240994A3 (en) 1995-12-13
DE69317411T2 (de) 1998-07-30
MY110149A (en) 1998-02-28

Similar Documents

Publication Publication Date Title
DE69532687T2 (de) Pharmazeutische zusammensetzungen zur vorbeugung und behandlung der ulzerativen kolitis
EP0633879B1 (en) Enantiomeric 1-phenyl-2-(2-pyridinyl)ethylamine for the treatment of neurodegenerative disorders
KR100412154B1 (ko) N-프로파길-1-아미노인단의r-에난시오머,염,및그들의조성물의사용
HK1009331B (en) Enantiomeric 1-phenyl-2-(2-pyridinyl) ethylamine for the treatment of neurodegenerative disorders
EP0691957B1 (en) (s)-alpha-phenyl-2-pyridineethanamine (s)-malate and its use as a medicament
JPH06293761A (ja) スピロ橋かけ型および非橋かけ型複素環式化合物
US5455259A (en) Compounds for the treatment of neurodegenerative disorders
DE69230498T2 (de) 2-Pyrazinylethylamin-Derivate und ihre Verwendung als Arzneimittel.
EP0691958B1 (en) (s)-alpha-phenyl-2-pyridineethanamine benzoate and its use as a medicament
AU639722B2 (en) Use of arylalkylamides in the treatment of neurodegenerative diseases
TW390875B (en) (S) -<alpha>-phenyl-2-pyridineethanamine (S)-malate useful in therary, its perparing process and pharmaceutical composition comprising the same
WO2004071381A2 (de) Arzneimittel enthaltend substituierte 2-aryl-aminoessigsäure-verbindungen und/oder substituierte 2-heteroaryl-aminoessigsäure-verbindungen

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20130331